Latest Articles

Publication Date
Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge - Cureus

Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge Cureus

Published: May 21, 2026, 4:13 p.m.
ADVANTAGE: Advanced discovery of visceral analgesics by neuroimmune targets and the genetics of extreme human phenotype, a study protocol.

Chronic visceral pain affects over 20% of adults globally but remains poorly understood, significantly impacting quality of life and healthcare costs. Limited understanding and diagnostic misconceptions hinder effective management, particularly …

Published: May 21, 2026, midnight
Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge.

Umbilical endometriosis, or Villar's nodule, is a rare form of cutaneous endometriosis in which ectopic endometrial tissue involves the umbilical skin. It may occur without any history of abdominal or …

Published: May 21, 2026, midnight
Piezo1 mediates hypoxia-induced endometriosis fibrosis via the mtDNA -dependent cGAS-STING pathway.

Endometriosis (EMs) is a prevalent gynecological disorder characterized by the ectopic growth of functional endometrial tissue, and its fibrotic pathology represents a primary contributor to chronic pain and infertility in …

Published: May 19, 2026, midnight
Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways.

Endometriosis is a chronic, estrogen-dependent disorder defined by ectopic endometrial-like tissue growth, persistent inflammation, and aberrant innervation. Emerging evidence indicates that disease progression and symptom severity are driven by a …

Published: May 19, 2026, midnight
Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report.

Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …

Published: May 19, 2026, midnight
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Yahoo

Published: May 18, 2026, 4:44 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks

Published: May 18, 2026, 11:10 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!